Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions

+1 2315155523

South Korea Next Generation Sequencing Market

South Korea Next Generation Sequencing Market Report 2026

South Korea Next Generation Sequencing Market by Service Type (Human Genome Sequencing, Gene Regulation Services, Other Services), by Workflow (Sequencing, Library Preparation, Data Analysis, Pre-sequencing QC), by End User (Universities & Research Entities, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies), by Application (Oncology, Reproductive Health, Rare Disease, Infectious Disease), by Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing, RNA Sequencing), Forecast 2026-2034

Updated On : Nov 4, 2026|

About Market Lens IQ

Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.

At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.

South Korea Next Generation Sequencing Market

South Korea Next Generation Sequencing Market Report 2026

Updated On : Nov 4, 2026|

South Korea Next Generation Sequencing Market CAGR, market size, market share

Executive Overview: South Korea's NGS Market at an Inflection Point

South Korea's next-generation sequencing (NGS) market is undergoing a structural acceleration, driven by the convergence of national precision-medicine policy, an aging population, and a highly concentrated hospital-lab ecosystem. Our proprietary bottom-up modeling estimates the market at $0.28 billion in 2025, expanding to $0.33 billion in 2026 and reaching $0.62 billion by 2033, a CAGR of 18.9% over 2026–2033. South Korea accounts for roughly 11–13% of Asia-Pacific NGS demand, making it the region's fourth-largest national market behind China, Japan, and India.

South Korea Next Generation Sequencing Market Size (In Million)

1.0B

800.0M

600.0M

400.0M

200.0M

330.0 M

2025

392.0 M

2026

467.0 M

2027

555.0 M

2028

660.0 M

2029

784.0 M

2030

932.0 M

2031

South Korea Next Generation Sequencing Market Size (In Million)
Year	Market Size
2025	330.0 M
2026	392.0 M
2027	467.0 M
2028	555.0 M
2029	660.0 M
2030	784.0 M
2031	932.0 M

Key structural metrics for 2025:

Services represent 58.4% of revenue, reflecting heavy outsourcing of sequencing runs and bioinformatics by hospital consortia and research institutes.
Diagnostics is the leading application at 34.6%, anchored by clinical oncology, prenatal cell-free DNA screening, and rare-disease panels.
Whole genome sequencing (WGS) holds 28.4% of technology revenue, reinforced by national biobanking and rare-disease diagnostic programs.

Market Drivers: Policy, Oncology Burden, and Outsourcing Economics

National genomics infrastructure. The Korea Bio Big-Data project and the Korea National Institute of Health's biobank initiatives have institutionalized population-scale sequencing, creating durable procurement demand for platforms, reagents, and interpretation services.
Oncology diagnostics mandate. NGS-based tumor genotyping for EGFR, ALK, and BRAF alterations has moved from optional to standard of care in non-small cell lung cancer and other solid tumors. With cancer remaining the leading cause of mortality in Korea, hospital adoption of liquid biopsy and tissue-based comprehensive genomic profiling continues to climb.
Outsourcing economics. Capital intensity of sequencers and the scarcity of certified bioinformaticians push hospitals and biotechs toward service providers. Korea's contract sequencing leaders serve as the de facto infrastructure layer for small and mid-sized research groups.
Reproductive health demand. Falling fertility rates and rising maternal age have expanded NIPT uptake, making reproductive applications the largest clinical NGS revenue pool in Korea alongside oncology.

Restraints and Challenges

Bioinformatics talent shortage. The gap between sequencing output and interpretation capability extends turnaround times and constrains clinical translation outside tertiary hospitals.
Reimbursement friction. Coverage for comprehensive genomic profiling is expanding but remains uneven across panel sizes and cancer indications, limiting volume growth in community hospitals.
Data privacy and cross-border transfer rules. Korea's Personal Information Protection Act imposes strict consent and transfer requirements on genomic data, complicating multinational collaborations and cloud-based analysis.
Fragmented regulatory pathways. Parallel oversight by the Ministry of Food and Drug Safety and the Ministry of Health and Welfare slows market entry for novel assays.

Segmentation Analysis

By service type: Human genome sequencing dominates due to clinical WGS adoption, followed by gene regulation and transcriptomics services as immunotherapy and functional genomics research expands in Seoul and Daejeon bioclusters.

By workflow: Sequencing services capture the majority of revenue at over 55%, while library preparation, data analysis, and pre-sequencing QC grow faster as automation penetrates hospital labs.

By end user: Universities and research entities form the largest base at roughly 52%, but hospitals and clinical laboratories are the fastest-growing channel as reimbursement pathways mature.

Competitive Landscape and Strategic Developments

South Korea's NGS market is moderately concentrated, with global platform leaders (Illumina, Thermo Fisher Scientific, MGI Tech, Oxford Nanopore, Pacific Biosciences) supplying instruments and consumables while domestic service providers anchor downstream demand. Key recent developments:

2025: Korea's national biobank expanded whole-genome sequencing cohorts, reinforcing government-backed demand.
2024–2025: Major Korean service providers invested in automated library preparation to reduce turnaround times and reagent costs.
2025: Expanded reimbursement discussions for comprehensive genomic profiling in oncology signals a positive volume inflection for clinical NGS.
2024: Cloud-based genomic analysis partnerships between Korean bioinformatics firms and hospital consortia accelerated data interpretation scale.

Regional Distribution Within South Korea

Demand is heavily weighted toward the Seoul Capital Area, which houses the largest tertiary hospitals, contract sequencing providers, and biotech headquarters. Gyeonggi and Incheon capture satellite research and manufacturing activity, while Daejeon's research cluster and regional university hospitals anchor the Chungcheong and Gyeongsang corridors.

South Korea Next Generation Sequencing Market Regional Market Share

Loading chart...

South Korea Next Generation Sequencing Market Regional Market Share
Region	Market Share (%)
Seoul Capital Area	0.58%
Gyeonggi & Incheon	0.18%
Gyeongsang Region	0.12%
Chungcheong Region	0.08%
Jeolla & Jeju	0.04%

Strategic Outlook and White-Space Opportunities

AI-enabled variant interpretation is the clearest white space, addressing the bioinformatics bottleneck.
Liquid biopsy scaling in oncology offers the fastest revenue ramp alongside reimbursement expansion.
Population genomics partnerships with government agencies create multi-year revenue visibility for service providers.
Cross-border data governance solutions will differentiate providers serving multinational pharma trials.

South Korea Next Generation Sequencing Market Regional Market Share

Higher Coverage

Lower Coverage

No Coverage

South Korea Next Generation Sequencing Market REPORT HIGHLIGHTS

Choose License Type

Author

Amit Mardhekar

Research Analyst

I am a Research Analyst driving market intelligence at the intersection of Healthcare, Life Sciences, Materials, and Real Estate and Construction landscapes. Specializing in Pharmaceuticals, Medical Devices, and Construction infrastructure, my expertise lies in market sizing, trend analysis, and demand forecasting. I focus on translating regulatory shifts and complex industry trends into strategic insights that help global clients identify and confidently seize new growth opportunities.

Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Customized Evaluation of Competitive Landscape to Meet Your Needs
Tailored Customization to Address Other Specific Requirements

Client Reviews

5.0

Verified Purchase

“As requested- presale engagement was good, your perseverance, support and prompt responses were noted. Your follow up with vm’s were much appreciated. Happy with the final report and post sales by your team. ”

Shankar Godavarti

Verified

Global Product, Quality & Strategy Executive- Principal Innovator at Donaldson

Verified Purchase

“I have received the report already. Thanks you for your help.it has been a pleasure working with you. Thank you again for a good quality report ”

Jared Wan

Verified

Analyst at Providence Strategic Partners at Petaling Jaya

Verified Purchase

“The response was good, and I got what I was looking for as far as the report. Thank you for that.”

Erik Perison

Verified

US TPS Business Development Manager at Thermon

Verified Purchase

“Yes, as a matter of fact we are totally satisfied with both reports that we have purchased and will continue to do so during this process of the internationalization of our brand.”

Santiago Mejia Molina

Verified

Internationalization Director

Verified Purchase

“We are using your report, and it gave us valuable information." ”

Olaf Gleibe

Verified

Head of Product Management and Marketing

1/5

Choose License Type

Author

Amit Mardhekar

Research Analyst

Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Customized Evaluation of Competitive Landscape to Meet Your Needs
Tailored Customization to Address Other Specific Requirements

Head of Product Management and Marketing

1/5

Executive Overview: South Korea's NGS Market at an Inflection Point

South Korea Next Generation Sequencing Market Size (In Million)

1.0B

800.0M

600.0M

400.0M

200.0M

330.0 M

2025

392.0 M

2026

467.0 M

2027

555.0 M

2028

660.0 M

2029

784.0 M

2030

932.0 M

2031

South Korea Next Generation Sequencing Market Size (In Million)
Year	Market Size
2025	330.0 M
2026	392.0 M
2027	467.0 M
2028	555.0 M
2029	660.0 M
2030	784.0 M
2031	932.0 M

Key structural metrics for 2025:

Services represent 58.4% of revenue, reflecting heavy outsourcing of sequencing runs and bioinformatics by hospital consortia and research institutes.
Diagnostics is the leading application at 34.6%, anchored by clinical oncology, prenatal cell-free DNA screening, and rare-disease panels.
Whole genome sequencing (WGS) holds 28.4% of technology revenue, reinforced by national biobanking and rare-disease diagnostic programs.

Market Drivers: Policy, Oncology Burden, and Outsourcing Economics

National genomics infrastructure. The Korea Bio Big-Data project and the Korea National Institute of Health's biobank initiatives have institutionalized population-scale sequencing, creating durable procurement demand for platforms, reagents, and interpretation services.
Oncology diagnostics mandate. NGS-based tumor genotyping for EGFR, ALK, and BRAF alterations has moved from optional to standard of care in non-small cell lung cancer and other solid tumors. With cancer remaining the leading cause of mortality in Korea, hospital adoption of liquid biopsy and tissue-based comprehensive genomic profiling continues to climb.
Outsourcing economics. Capital intensity of sequencers and the scarcity of certified bioinformaticians push hospitals and biotechs toward service providers. Korea's contract sequencing leaders serve as the de facto infrastructure layer for small and mid-sized research groups.
Reproductive health demand. Falling fertility rates and rising maternal age have expanded NIPT uptake, making reproductive applications the largest clinical NGS revenue pool in Korea alongside oncology.

Restraints and Challenges

Bioinformatics talent shortage. The gap between sequencing output and interpretation capability extends turnaround times and constrains clinical translation outside tertiary hospitals.
Reimbursement friction. Coverage for comprehensive genomic profiling is expanding but remains uneven across panel sizes and cancer indications, limiting volume growth in community hospitals.
Data privacy and cross-border transfer rules. Korea's Personal Information Protection Act imposes strict consent and transfer requirements on genomic data, complicating multinational collaborations and cloud-based analysis.
Fragmented regulatory pathways. Parallel oversight by the Ministry of Food and Drug Safety and the Ministry of Health and Welfare slows market entry for novel assays.

Segmentation Analysis

By end user: Universities and research entities form the largest base at roughly 52%, but hospitals and clinical laboratories are the fastest-growing channel as reimbursement pathways mature.

Competitive Landscape and Strategic Developments

2025: Korea's national biobank expanded whole-genome sequencing cohorts, reinforcing government-backed demand.
2024–2025: Major Korean service providers invested in automated library preparation to reduce turnaround times and reagent costs.
2025: Expanded reimbursement discussions for comprehensive genomic profiling in oncology signals a positive volume inflection for clinical NGS.
2024: Cloud-based genomic analysis partnerships between Korean bioinformatics firms and hospital consortia accelerated data interpretation scale.

Regional Distribution Within South Korea

South Korea Next Generation Sequencing Market Regional Market Share

Loading chart...

South Korea Next Generation Sequencing Market Regional Market Share
Region	Market Share (%)
Seoul Capital Area	0.58%
Gyeonggi & Incheon	0.18%
Gyeongsang Region	0.12%
Chungcheong Region	0.08%
Jeolla & Jeju	0.04%

Strategic Outlook and White-Space Opportunities

AI-enabled variant interpretation is the clearest white space, addressing the bioinformatics bottleneck.
Liquid biopsy scaling in oncology offers the fastest revenue ramp alongside reimbursement expansion.
Population genomics partnerships with government agencies create multi-year revenue visibility for service providers.
Cross-border data governance solutions will differentiate providers serving multinational pharma trials.

South Korea Next Generation Sequencing Market Regional Market Share

Higher Coverage

Lower Coverage

No Coverage

South Korea Next Generation Sequencing Market REPORT HIGHLIGHTS

Aspects	Details
Study Period	2020-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2020-2025
Growth Rate	CAGR of 18.9% from 2020-2034
Segmentation	By Service Type Human Genome Sequencing Gene Regulation Services Other Services By Workflow Sequencing Library Preparation Data Analysis Pre-sequencing QC By End User Universities & Research Entities Hospitals & Clinics Pharmaceutical & Biotechnology Companies By Application Oncology Reproductive Health Rare Disease Infectious Disease By Technology Whole Genome Sequencing Whole Exome Sequencing Targeted Sequencing RNA Sequencing By Geography

1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Objective
- 1.4. Definitions and Assumptions
2. Executive Summary
- 2.1. Market Snapshot
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Challenges
- 3.3. Market Trends
- 3.4. Market Opportunity
4. Market Factor Analysis
- 4.1. Porters Five Forces
  - 4.1.1. Bargaining Power of Suppliers
  - 4.1.2. Bargaining Power of Buyers
  - 4.1.3. Threat of New Entrants
  - 4.1.4. Threat of Substitutes
  - 4.1.5. Competitive Rivalry
- 4.2. PESTEL analysis
- 4.3. BCG Analysis
  - 4.3.1. Stars (High Growth, High Market Share)
  - 4.3.2. Cash Cows (Low Growth, High Market Share)
  - 4.3.3. Question Mark (High Growth, Low Market Share)
  - 4.3.4. Dogs (Low Growth, Low Market Share)
- 4.4. Ansoff Matrix Analysis
- 4.5. Supply Chain Analysis
- 4.6. Regulatory Landscape
- 4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
- 4.8. MIQ Analyst Note
5. Market Analysis, Insights and Forecast, 2020-2034
- 5.1. Market Analysis, Insights and Forecast - by Service Type
  - 5.1.1. Human Genome Sequencing
  - 5.1.2. Gene Regulation Services
  - 5.1.3. Other Services
- 5.2. Market Analysis, Insights and Forecast - by Workflow
  - 5.2.1. Sequencing
  - 5.2.2. Library Preparation
  - 5.2.3. Data Analysis
  - 5.2.4. Pre-sequencing QC
- 5.3. Market Analysis, Insights and Forecast - by End User
  - 5.3.1. Universities & Research Entities
  - 5.3.2. Hospitals & Clinics
  - 5.3.3. Pharmaceutical & Biotechnology Companies
- 5.4. Market Analysis, Insights and Forecast - by Application
  - 5.4.1. Oncology
  - 5.4.2. Reproductive Health
  - 5.4.3. Rare Disease
  - 5.4.4. Infectious Disease
- 5.5. Market Analysis, Insights and Forecast - by Technology
  - 5.5.1. Whole Genome Sequencing
  - 5.5.2. Whole Exome Sequencing
  - 5.5.3. Targeted Sequencing
  - 5.5.4. RNA Sequencing
- 5.6. Market Analysis, Insights and Forecast - by Region
6. Competitive Analysis
- 6.1. Company Profiles
  - 6.1.1. Illumina
    - 6.1.1.1. Company Overview
    - 6.1.1.2. Products
    - 6.1.1.3. Company Financials
    - 6.1.1.4. SWOT Analysis
  - 6.1.2. Thermo Fisher Scientific
    - 6.1.2.1. Company Overview
    - 6.1.2.2. Products
    - 6.1.2.3. Company Financials
    - 6.1.2.4. SWOT Analysis
  - 6.1.3. MGI Tech
    - 6.1.3.1. Company Overview
    - 6.1.3.2. Products
    - 6.1.3.3. Company Financials
    - 6.1.3.4. SWOT Analysis
  - 6.1.4. Oxford Nanopore Technologies
    - 6.1.4.1. Company Overview
    - 6.1.4.2. Products
    - 6.1.4.3. Company Financials
    - 6.1.4.4. SWOT Analysis
  - 6.1.5. Pacific Biosciences
    - 6.1.5.1. Company Overview
    - 6.1.5.2. Products
    - 6.1.5.3. Company Financials
    - 6.1.5.4. SWOT Analysis
  - 6.1.6. Macrogen
    - 6.1.6.1. Company Overview
    - 6.1.6.2. Products
    - 6.1.6.3. Company Financials
    - 6.1.6.4. SWOT Analysis
  - 6.1.7. BGI Genomics
    - 6.1.7.1. Company Overview
    - 6.1.7.2. Products
    - 6.1.7.3. Company Financials
    - 6.1.7.4. SWOT Analysis
  - 6.1.8. Qiagen
    - 6.1.8.1. Company Overview
    - 6.1.8.2. Products
    - 6.1.8.3. Company Financials
    - 6.1.8.4. SWOT Analysis
  - 6.1.9. Roche Life Sciences
    - 6.1.9.1. Company Overview
    - 6.1.9.2. Products
7. Research Methodology

List of Figures

Figure 1: South Korea Next Generation Sequencing Market Revenue Breakdown (Million, %) by Product 2026 & 2034
Figure 2: South Korea Next Generation Sequencing Market Value Share (%), by Service Type 2026 & 2034
Figure 3: South Korea Next Generation Sequencing Market Value Share (%), by Workflow 2026 & 2034
Figure 4: South Korea Next Generation Sequencing Market Value Share (%), by End User 2026 & 2034
Figure 5: South Korea Next Generation Sequencing Market Value Share (%), by Application 2026 & 2034
Figure 6: South Korea Next Generation Sequencing Market Value Share (%), by Technology 2026 & 2034
Figure 7: South Korea Next Generation Sequencing Market Share (%) by Company 2026

List of Tables

Table 1: South Korea Next Generation Sequencing Market Revenue Million Forecast, by Service Type 2020 & 2034
Table 2: South Korea Next Generation Sequencing Market Revenue Million Forecast, by Workflow 2020 & 2034
Table 3: South Korea Next Generation Sequencing Market Revenue Million Forecast, by End User 2020 & 2034
Table 4: South Korea Next Generation Sequencing Market Revenue Million Forecast, by Application 2020 & 2034
Table 5: South Korea Next Generation Sequencing Market Revenue Million Forecast, by Technology 2020 & 2034
Table 6: South Korea Next Generation Sequencing Market Revenue Million Forecast, by Region 2020 & 2034

Research Methodology & Data Sources

Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.

Primary Research

70–80% of inputs derived from primary interviews with NGS service providers, hospital laboratory directors, and biopharma translational leads in South Korea.
Interviews conducted with 120+ stakeholders across Seoul, Daejeon, and Gyeonggi bioclusters.
Company types interviewed include contract sequencing service providers, hospital genomics laboratories, in-vitro diagnostics manufacturers, biopharma translational research teams, and academic genomics centers.
Stakeholder designations include Laboratory Director, Chief Genomics Officer, Translational Research Lead, and Procurement Manager.
Regulatory and industry bodies consulted include the Korea Ministry of Food and Drug Safety, Korea National Institute of Health, Korea Bioindustry Association, and the Korean Society for Laboratory Medicine.
Quantitative metrics collected include annual sequencing run volumes, installed sequencer base, average revenue per sequencing service contract, and reimbursement claim volumes for genomic profiling.

Key Stakeholders Interviewed

Key Stakeholders Interviewed
Stakeholder Role	Interview Share (%)
Laboratory Director	32%
Chief Genomics Officer	24%
Translational Research Lead	26%
Procurement Manager	18%

Industry Ecosystem Breakdown

Industry Ecosystem Breakdown
Company Type	Representation (%)
Contract sequencing service providers	35%
Hospital genomics laboratories	25%
IVD and assay manufacturers	18%
Biopharma translational research teams	12%
Academic genomics centers	10%

Secondary Research & Industry Benchmarking

20–30% of inputs derived from secondary sources including peer-reviewed literature, government statistical releases, and trade association reports.
Financial and corporate data verified via Bloomberg, Factiva, Hoovers, and PitchBook.
Official sources include the Korea National Institute of Health (http://nih.go.kr), Korea Ministry of Food and Drug Safety (http://mfds.go.kr), Korea Bioindustry Association (http://kobio.or.kr), and the Korean Society for Laboratory Medicine (http://kslm.org).
Benchmarks triangulated against Asia-Pacific NGS regional data and global sequencing service benchmarks.

Demand Modeling & Market Estimation

Simultaneous top-down and bottom-up modeling applied, with multi-level data triangulation across service type, workflow, end user, and application segments.
Bottom-up estimation based on sequencing run volumes multiplied by average revenue per run, cross-validated with installed base and reagent consumption data.
Demand-side modeling incorporates hospital NGS test reimbursement volumes, national biobank sequencing targets, and biopharma trial sequencing expenditure.
Segment-level CAGR projections built from procedure volume forecasts, reimbursement policy trajectories, and platform replacement cycles.

Data Accuracy & Quality Check

Guaranteed estimated data accuracy of 85–90%, validated through multi-level triangulation.
Cross-validation of primary interview data against audited financial disclosures and government procurement records.
Every report updated to the date of purchase, incorporating the latest reimbursement decisions, biobank contracts, and platform launches.
Sanity checks applied to segment shares to ensure consistency with regional and global NGS benchmarks.

Tailored for you

South Korea Next Generation Sequencing Market Report 2026

About Market Lens IQ

Tailored for you

South Korea Next Generation Sequencing Market Report 2026

Executive Overview: South Korea's NGS Market at an Inflection Point

Market Drivers: Policy, Oncology Burden, and Outsourcing Economics

Restraints and Challenges

Segmentation Analysis

Competitive Landscape and Strategic Developments

Regional Distribution Within South Korea

Strategic Outlook and White-Space Opportunities

South Korea Next Generation Sequencing Market Regional Market Share

Shankar Godavarti

Jared Wan

Erik Perison

Santiago Mejia Molina

Olaf Gleibe

Shankar Godavarti

Jared Wan

Erik Perison

Santiago Mejia Molina

Olaf Gleibe

Related Reports

Executive Overview: South Korea's NGS Market at an Inflection Point

Market Drivers: Policy, Oncology Burden, and Outsourcing Economics

Restraints and Challenges

Segmentation Analysis

Competitive Landscape and Strategic Developments

Regional Distribution Within South Korea

Strategic Outlook and White-Space Opportunities

South Korea Next Generation Sequencing Market Regional Market Share

Table of Contents

List of Figures

List of Tables

Frequently Asked Questions

1. What is the size of the South Korea next generation sequencing market?

2. Which segment leads the South Korea NGS market?

3. What are the key drivers of NGS adoption in South Korea?

4. Which companies are active in the South Korea NGS market?

5. What is the growth forecast for South Korea NGS market?

Research Methodology & Data Sources

Primary Research

Key Stakeholders Interviewed

Industry Ecosystem Breakdown

Secondary Research & Industry Benchmarking

Demand Modeling & Market Estimation

Data Accuracy & Quality Check